| Literature DB >> 27851998 |
M-R Lin1, S-L Yang2, Y-N Gong3, C-C Kuo1, C-H Chiu1, C-J Chen1, Y-C Hsieh1, C-Y Kuo1, C-W Fang4, K-C Tsao5, Y-C Huang6.
Abstract
OBJECTIVES: We studied paediatric patients with human adenovirus (HAdV) infection during the 2011 outbreak in northern Taiwan to define the clinical features of different HAdV genotypes in children.Entities:
Keywords: Adenovirus; Children; Genotype 7; Outbreak; Taiwan
Mesh:
Substances:
Year: 2016 PMID: 27851998 PMCID: PMC7129580 DOI: 10.1016/j.cmi.2016.11.004
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Fig. 1Flow chart describing case selection. a Patients excluded due to insufficient samples. b HAdV-2, -3 and -7, human adenovirus type 2, 3, and 7. c LRTI, lower respiratory tract infection; PICU, paediatric intensive care unit. d LRTI patients (14/75) exhibiting severe respiratory distress. e These patients included three with neurological dysfunction, two suffering from shock, and one with massive bleeding in the gastrointestinal tract.
Demographic data and clinical characteristics of 621 hospitalized children infected with different HAdV genotypes
| Characteristics | HAdV-2, | HAdV-3, | HAdV-7, | p |
|---|---|---|---|---|
| Case number | 58 | 422 | 141 | |
| Male | 33 (56.9) | 237 (56.1) | 89 (63.1) | 0.346 |
| Age, mean ± SD (months) | 38.90±23.01 | 61.59±30.54 | 57.98±46.52 | <0.001 |
| >3 years | 31 (53.4) | 350 (82.9) | 84 (59.6) | <0.001 |
| General symptoms | ||||
| Fever | 54 (93.1) | 417 (98.8) | 138 (97.9) | 0.012 |
| Fever >39°C | 51 (87.9) | 396 (93.8) | 133 (94.3) | 0.209 |
| Duration, mean ± SD (days) | 5.33±3.03 | 5.39±2.13 | 6.58±2.90 | <0.001 |
| >7 days | 17 (29.3) | 36 (8.5) | 40 (28.4) | <0.001 |
| Decreased appetite | 49 (84.5) | 352 (83.4) | 128 (90.8) | 0.102 |
| Decreased activity | 33 (56.9) | 282 (66.8) | 116 (82.3) | <0.001 |
| Respiratory symptoms | ||||
| Cough | 47 (81.0) | 362 (85.8) | 106 (75.2) | 0.014 |
| Rhinorrhoea | 40 (69.0) | 306 (72.5) | 79 (56.0) | 0.007 |
| Nasal congestion | 29 (50.0) | 234 (55.5) | 53 (37.6) | 0.001 |
| Sore throat | 17 (29.3) | 189 (44.8) | 58 (41.1) | 0.077 |
| Exudate coating | 21 (36.2) | 202 (47.9) | 47 (33.9) | 0.005 |
| Oral ulcers | 1 (1.7) | 24 (5.7) | 18 (12.8) | 0.004 |
| Conjunctivitis | 9 (15.5) | 79 (18.7) | 24 (17.0) | 0.786 |
| Extrapulmonary symptoms | ||||
| Skin rash | 4 (6.9) | 22 (5.2) | 17 (12.1) | 0.021 |
| Headache | 4 (6.9) | 51 (12.1) | 11 (7.9) | 0.232 |
| Abdominal pain | 12 (20.7) | 124 (29.4) | 38 (27.0) | 0.365 |
| Vomiting | 13 (22.4) | 119 (28.2) | 41 (29.1) | 0.611 |
| Diarrhoea | 10 (17.2) | 117 (27.7) | 57 (27.0) | 0.365 |
| Underlying diseases | 1 (1.7) | 10 (2.4) | 3 (2.1) | 0.947 |
| Neurology | 0 | 2 | 1 | |
| Pulmonary | 0 | 1 | 0 | |
| Gastrointestinal | 0 | 1 | 2 | |
| Cardiovascular | 0 | 0 | 0 | |
| Others | 1 | 6 | 0 | |
| Complication | ||||
| LRTI | 3 (3.4) | 40 (9.0) | 32 (20.6) | <0.001 |
| Respiratory distress | 1 (1.7) | 13 (3.1) | 8 (5.7) | 0.259 |
| Intubation | 1 (1.7) | 3 (0.7) | 3 (2.1) | 0.333 |
| Duration (days) | 2 | 6.67±0.58 | 25.33±32.62 | 0.017 |
| Pneumonia patch | 3 (6.9) | 32 (8.5) | 28 (19.9) | <0.001 |
| Single lobe | 100% | 66% | 61% | |
| Multiple lobes | 0% | 34% | 39% | |
| Pleural effusion | 0 | 3 (0.7) | 8 (5.7) | <0.001 |
| PICU | 1 (1.7) | 8 (1.9) | 11 (7.8) | <0.001 |
| Duration (days) | 4 | 6.38±2.72 | 11.45±18.93 | 0.114 |
| Mortality | 0 | 0 | 3 | |
| ECMO use | 0 | 0 | 2 | |
| Antibiotics treatment | 30 (51.7) | 275 (65.2) | 76 (53.9) | <0.001 |
| Co-infection with | 0 | 5 (1.2) | 4 (2.8) | 0.305 |
| Co-infection with pneumococcus | 0 | 0 | 4 (2.8) | 0.15 |
| LOS (days) | 3.84±1.25 | 4.40±3.69 | 6.18±7.32 | <0.001 |
Abbreviations: ECMO, extracorporeal membrane oxygenation; HAdV, human adenovirus; LOS, length of hospital stay; LRTI, lower respiratory tract infection; PICU, paediatric intensive care unit.
Statistical significance: p <0.05 via post hoc analysis.
Laboratory findings from 621 hospitalized children infected with different HAdV genotypes
| Laboratory data | HAdV-2, | HAdV-3, | HAdV-7, | p |
|---|---|---|---|---|
| Case number | 58 | 422 | 141 | |
| Haemogram | ||||
| WBC count (1000/μL) | 15.36±5.85 | 12.93±5.48 | 9.39±4.69 | <0.001 |
| Peak or nadir | 15.80±5.74 | 13.19±5.55 | 9.92±5.00 | <0.001 |
| <5000/μL | 0 | 7 (1.7) | 17 (12.1) | <0.001 |
| >15 000/μL | 28 (48.3) | 117 (27.7) | 18 (12.7) | <0.001 |
| Hb, mean±SD (g/dl) | 13.51±5.63 | 9.92±5.00 | 12.69±5.69 | 0.126 |
| Platelet, mean±SD (1000/μL) | 297.74±101.05 | 249.58±72.74 | 213.74±76.21 | <0.001 |
| <150 000/μL | 0 | 12 (2.8) | 22 (15.6) | <0.001 |
| >450 000/μL | 4 (6.9) | 8 (1.9) | 1 (0.7) | <0.001 |
| Biochemistry | ||||
| CRP (mg/L) | 42.87±37.07 | 77.81±56.39 | 38.46±37.86 | <0.001 |
| Peak CRP (mg/L) | 46.75±38.97 | 84.47±55.15 | 44.83±39.76 | <0.001 |
| <40 mg/L | 30 (51.7) | 93 (22.0) | 75 (53.2) | <0.001 |
| >100 mg/L | 7 (12.1) | 153 (36.3) | 14 (9.9) | <0.001 |
| BUN, mean±SD (mg/dL) | 8.99±3.54 | 7.84±3.55 | 8.52±5.78 | 0.463 |
| Cr, mean±SD (mg/dL) | 0.33±0.10 | 0.37±0.11 | 0.62±1.79 | 0.146 |
| >1.0 mg/dL | 2/24 (8.3) | 5/176 (2.8) | 7/66 (10.6) | 0.043 |
| AST (U/L) | 50.91±79.06 | 41.02±66.22 | 57.97±57.66 | 0.104 |
| >3-fold of normal value | 0/33 | 0/250 | 3/88 (3.4) | 0.008 |
Abbreviations: AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; HAdV, human adenovirus; Hb, haemoglobin; WBC, white blood cell;.
Note: Haemogram and CRP were checked in all 621 cases. Cr was checked in 266 cases (HAdV-2: 24 cases; HAdDV-3: 176 cases; and HAdV-7: 66 cases) and AST was checked in 371 cases (HAdV-2: 24 cases; HAdDV-3: 176 cases; and HAdV-7: 66 cases).
First laboratory examination on admission.
The highest or lowest laboratory value during hospitalization.
Comparison of clinical features between 621 hospitalized children with or without LRTIs or PICU admission
| Characteristics | LRTI, | Non-LRTI, | p | PICU, | Non-PICU, | p |
|---|---|---|---|---|---|---|
| Case number | 75 | 546 | 20 | 601 | ||
| Genotypes | ||||||
| HAdV-2 | 3 (4.0) | 55 (10.1) | 0.09 | 2 (10.0) | 56 (9.3) | 0.918 |
| HAdV-3 | 40 (53.3) | 382 (69.9) | 0.004 | 8 (40.0) | 414 (68.9) | 0.006 |
| HAdV-7 | 32 (42.7) | 109 (19.9) | <0.001 | 10 (50.0) | 131 (21.8) | 0.003 |
| Fever | 74 (98.6) | 535 (98.0) | 0.757 | 19 (95.0) | 590 (98.2) | 0.311 |
| Fever>39°C | 72 (96.0) | 508 (93.0) | 0.331 | 18 (90.0) | 561 (93.5) | 0.536 |
| Duration (days) | 7.96±7.46 | 4.20±3.37 | <0.001 | 8.7±5.31 | 5.55±2.26 | <0.001 |
| >7 days | 36 (48.0) | 57 (10.4) | <0.001 | 11 (55) | 82 (13.6) | <0.001 |
| Peak or nadir leucocyte count, mean±SD | 12.99±7.46 | 12.68±5.47 | 0.673 | 15.72±8.13 | 12.59±5.58 | 0.004 |
| <5000/μL | 8 (10.6) | 16 (2.9) | <0.001 | 2 (10.0) | 22 (3.7) | 0.148 |
| >15 000/μL | 22 (29.3) | 141 (25.8) | 0.227 | 9 (45.0) | 154 (25.6) | 0.053 |
| Peak CRP, mean±SD (mg/L) | 85.05±38.97 | 70.37±52.8 | 0.033 | 109.57±86.44 | 70.76±52.03 | 0.021 |
| >100 mg/L | 28 (37.7) | 146 (26.8) | 0.055 | 8 (40.0) | 166 (27.6) | 0.225 |
| Underlying diseases | 6 (8) | 8 (1.5) | 0.003 | 6 (30) | 8 (1.3) | <0.001 |
| Neurology | 3 | 0 | 3 | 0 | ||
| Pulmonary | 0 | 1 | 0 | 1 | ||
| Gastrointestinal | 3 | 0 | 3 | 0 | ||
| Cardiovascular | 0 | 7 | 0 | 7 | ||
| Others | 1 | 6 | 1 | 6 | ||
| Antibiotic treatment | 72 (96.0) | 309 (56.6) | <0.001 | 20 (100) | 361 (60.1) | <0.001 |
| LOS (days) | 9.13±9.42 | 4.20±3.37 | <0.001 | 20.0±17.89 | 4.24±2.17 | <0.001 |
Abbreviations: CRP, C-reactive protein; HAdV-2, -3 and -7, human adenoviruses types 2, 3 and 7; LOS, length of hospital stay; LRTI, lower respiratory tract infection; PICU, paediatric intensive care unit.
Fig. 2Phylogenetic tree for human adenovirus type 7 (HAdV-7) hexon genes. This phylogenetic tree was derived from the HAdV-7 hexon gene and evaluated using 1000 bootstrap replicates. The 25 sequences provided in this study are labelled by their strain names. Among these, 11 severe and 11 non-severe cases are marked with black and white circles, respectively, and three cases isolated in 2002 and 2004 are marked with triangles. Other sequences downloaded from GenBank are labelled by either accession number, location and year or by strain name.